This company listing is no longer active
MorphoSys Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
13 Aug 24 | BuyCHF 78,439,831 | Novartis AG | Company | 1,216,926 | CHF 64.46 | |
16 Jun 24 | BuyCHF 41,573,889 | Novartis AG | Company | 641,331 | CHF 64.82 | |
10 Jun 24 | BuyCHF 244,236,962 | Novartis AG | Company | 3,725,565 | CHF 65.56 | |
23 May 24 | BuyCHF 1,723,703,348 | Novartis AG | Company | 25,610,813 | CHF 67.30 | |
16 Apr 24 | BuyCHF 287,551,022 | Novartis AG | Company | 4,360,100 | CHF 65.96 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Private Companies | 215,483 | 0.34% |
Individual Insiders | 993,318 | 1.57% |
Hedge Funds | 1,890,000 | 2.98% |
Institutions | 25,905,490 | 40.9% |
Public Companies | 34,337,809 | 54.2% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
34,337,809 | CHF 2.2b | 4,220% | no data | |||
3,245,202 | CHF 204.0m | 12.6% | 0.02% | |||
1,890,000 | CHF 118.8m | 26% | 0.26% | |||
1,766,363 | CHF 111.0m | -6.05% | 0.18% | |||
1,711,331 | CHF 107.6m | 0% | 1.49% | |||
1,607,684 | CHF 101.1m | -14.6% | 0.07% | |||
1,337,552 | CHF 84.1m | -50% | 36.51% | |||
1,299,717 | CHF 81.7m | -11.3% | 0.12% | |||
1,192,607 | CHF 75.0m | -43.1% | 0.03% | |||
1,086,105 | CHF 68.3m | 190% | 0.04% | |||
1,010,913 | CHF 63.6m | 0% | 0.06% | |||
979,174 | CHF 61.6m | 0% | 0.02% | |||
975,441 | CHF 61.3m | 0% | no data | |||
931,680 | CHF 58.6m | 238% | 0.02% | |||
927,821 | CHF 58.3m | 0% | no data | |||
924,309 | CHF 58.1m | 15.7% | no data | |||
868,004 | CHF 54.6m | 30.8% | 0.02% | |||
835,292 | CHF 52.5m | 0% | 0.03% | |||
745,925 | CHF 46.9m | -65.3% | 0.01% | |||
649,979 | CHF 40.9m | -85.3% | 0.01% | |||
436,327 | CHF 27.4m | 0% | 0.3% | |||
370,484 | CHF 23.3m | -56.9% | no data | |||
362,463 | CHF 22.8m | 0% | 3.59% | |||
325,986 | CHF 20.5m | 4,030% | 0.07% | |||
289,931 | CHF 18.2m | -61.7% | 0.01% |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/08/05 21:26 |
End of Day Share Price | 2024/08/05 00:00 |
Earnings | 2024/03/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MorphoSys AG is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Olav Zilian | Baader Helvea Equity Research |
Brian Balchin | Barclays |
Rosie Turner | Barclays |